

NANODARU

We Deliver Hope

Company Presentation

JANUARY 2018

NANO DARU

Story

The NANO DARU Story

NANO DARU started up in 2011, and we've been on a nice, warm, hard-working and creative attitude ever since. From our beginnings as a NDDS formulation development company to launch the first nanoparticulate product in 2016, we've tried to stay true to our core beliefs and to deliver an exceptional experience for our community and patients.

In line with the company's policy, NANO DARU has successfully adapted experience and knowledge acquired overtime to present conditions, thereby enabling sustainable development. We are among the Iran's leading nanotech companies, with a promising development pipeline. Evolving year on year and always eager to work with like-minded collaborators, we owe a huge thanks to our community and investors for joining us on this awesome journey, and we hope that they will continue to be a part of our story.

Who We Are

Our Team

Founders, Managers and the Board

Navid Nateghian

Co-founder, Board Member & Business Development Manager

PharnD; PhD of Pharmaceutics



Navid Goodarzi

Co-founder, Board Member & CEO

PharmD; PhD of Pharmaceutics

M. Esfandiyari-manesh

Co-founder, Board Member & R&D Manager

MSc; PhD of Pharmaceutical Nanotechnology

Personnel



11	PhD
10	MSc
3	BSc
8	Associate

35
YEARS
On Average

What We Do

What we do
or
Going to do?



Nanoparticulate Systems

»

Including protein nanopparticles and polymeric nanoparticles (e.g. PACLINAB®



Microsphere Products

»

Including generic form of Branded products by internal development or joint development (EXOPIO®

Antibody Drug Conjugates

T-DM1

»

Conventional Dosage Forms

» Pantoprazole
Esomeprazole
Deferoxamine
etc.



PACLINAB (Nanoparticles) Vials

Calendula Fort Ointment

Calendula Ointment

Medicine Registration Certificate(Marketing Authorization)



PIPELINE

PACLINAB (Nanoparticles) Vials

EXOPID (Microspheres) Vials

Ado-trastuzumab emtansine (ADC) Vials

Triptorelin (Microspheres) Vials

Botulinum Gel

Sildenafil Gel

Pantoprazol Vials

Ciprofloxacin Vials

Deferoxamine Vials

Iohexole Vials

Palbociclib Capsules

Esomeprazol Vials

Teicoplanin Vials

Gadoterate Meglumin Vials

PACLINAB

Our First Success

Abraxane®

nanoparticle albumin bound paclitaxel



A single molecule of albumin can bind up to 6 or 7 molecules of paclitaxel[11]

Pacl nab

Paclitaxel

nab-Paclitaxel

Approved for MBC at 2005





Paclinab
Paclitaxel

nab-Paclitaxel

Approved for Pancreatic Cancer at 2013

nab® Technology Future

Area of Research	Phase I	Phase II	Phase III	Regulatory Filing & Approval[a]	Post-Approval Research[b]
Solid Tumors					
ABRAXANE® (paclitaxel protein-bound particles for injectable suspension) (albumin-bound) (US)/ (paclitaxel formulated as albumin-bound nanoparticles) (EU)					
Breast: Metastatic					
Breast: Metastatic (first-line, triple negative)					
Non-small cell lung: Advanced (first-line) (US, Japan)					
Non-small cell lung: Advanced (first-line) (EU)					
Pancreatic: Advanced (first-line)					
Pancreatic: Adjuvant					
Gastric: Metastatic (Japan)[c]					



ABI-007 ABI-008 ABI-009 ABI-010 ABI-011

Our Progress

جمهوری اسلامی ایران
وزارت بهداشت درمان و آموزش پزشکی
سازمان غذا و دارو

سازمان غذا و دارو IFDA

تاریخ صدور : ۱۳۹۵/۰۹/۲۹

۵۹۲۲۵۹۶۴۴۸۸۸۷۵۰۳

Issuance Date: 12/19/2016

M.A Number: 59225964488887503

پروانه ثبت فراورده

به استناد قانون مربوط به مقررات امور پزشکی دارویی و مواد خوردنی آشامیدنی مصوب سال ۱۳۳۴ و اصلاحات سال های ۱۳۶۲ و ۱۳۶۷ آیین نامه های مربوطه و تصویب جلسه مورخ **۱۳۹۵/۰۸/۱۱** کمیسیون قانونی ساخت و ورود، با ثبت فراورده **«پودر برای تهیه سوسپانسیون تزریقی پاکلینب ۱۰۰میلی گرم»** با نام غیر اختصاصی **«پودر برای تهیه سوسپانسیون تزریقی پکلی تاکسل ۱۰۰ mg»** به نام شرکت **نانو دارو پژوهان پردیس** به شناسه ملی **۱۰۳۲۰۶۰۴۴۳۷** و نشانی **«تهران-اتوبان شهید چمران خیابان باقرخان شرقی پلاک ۳۳ واحد۲»** موافقت شد. این پروانه ثبت تا تاریخ **۱۳۹۶/۰۹/۲۹** مشروط به رعایت ضوابط و مقررات اداره کل نظارت و ارزیابی دارو و مواد مخدر معتبر است.

Medicine Registration Certificate(Marketing Authorization)

With reference to article of the 1955 medical act and according to approval of the legal committee in ***11/1/2016*** *here by registration of* ***PACLINAB 100MG INJECTION, POWDER, FOR SUSPENSION*** *with international Non-Proprietary Name* ***PACLITAXEL 100 mg INJECTION, POWDER, FOR SUSPENSION*** *by* ***Nano Daru Pajuhan Pardis*** *as License holder (NATIONAL ID:* ***10320604437****, official address:* ***Unit2NO 33 East Baqerkhan St Chamran Highway Tehran Iran****) is agreed in accordance with laws and regulations currently in force.This license valid till* ***12/20/2017****.*

Akbar Abdollahiasl- Director General
مدیر کل نظارت و ارزیابی دارو- دکتر اکبر عبداللهی اصل

تذکر: اعتبار این پروانه، مشروط و منوط به استعلام برخط (online) بارکد دوبعدی و یا کد درج شده در آن از طریق سامانه های رسمی معرفی شده سازمان غذا و دارو می باشد. (راهنمای مربوطه در پورتال سازمان موجود است)
www.fda.gov.ir

تهران- روبروی در اصلی دانشگاه تهران- خیابان فخر رازی- نبش خیابان شهید وحید نظری- سازمان غذا و دارو
تلفن: ۶۶۴۶۷۲۶۸ نمابر: ۶۶۴۶۹۱۴۲ کد پستی: ۱۳۱۴۷۱۵۳۱۱



T-DM1

Alliance for Hope

Kadcyla

Ado-trustuzumab emtansine



Stages of Breast Cancer and Impact on Treatment

Early-stage breast cancer (Stages I and II) is different from advanced breast cancer (Stages III and IV). Most people with advanced breast cancer will receive medicine for the rest of their lives.



STAGE I	STAGE II	STAGE III	STAGE IV
Tumor is limited to the breast (<2 cm)	Tumor has spread to 1-2 lymph nodes in the breast (<5 cm)	Tumor has spread to 4-9 lymph nodes or to the chest wall or skin	Tumor has spread to distant organs

HER2+ metastatic Breast Cancer (mBC)

Roche

The target US and Top 5 EU population for 1L HER2+ metastatic breast cancer is ~18,000 patients (6,000 de novo and 12,000 adjuvant relapse)



The target US and Top 5 EU population for 2L-4L HER2+ metastatic breast cancer is ~26,000 patients (~14,000 US/~12,000 Top 5 EU)

	Adjuvant relapse	De Novo
1L Patients (Top5 EU)	6,400	3,300
1L Patients (US)	5,400	2,800

	HER2+ Rx opportunities	
	US	5 EU
2L	6,300	7,000
3L	4,700	3,200
4L	3,250	1,500



EXOPIO

The Light in the Dark

Opioid Addiction Treatment Options

- Methadone
- Buprenorphine
- Opium Tincture
- Oral Naltrexone
- Naloxone




VIVITROL®

Oral Naltrexone

30 tabs/month*
(1-2 tabs/day)

1984

VIVITROL®
(naltrexone for extended-release injectable suspension)



1/month

2011

*Based on a month with 30 days.

Prescribing Considerations	Extended-Release Injectable Naltrexone	Buprenorphine	Methadone
Frequency of Administration	Monthly	Daily	Daily
Route of Administration	Intramuscular injection in the gluteal muscle by healthcare professional.	Oral tablet or film is dissolved under the tongue. Can be taken at a physician's office or at home.	Oral (liquid) consumption usually witnessed at an OTP, until the patient receives take-home doses.
Restrictions on Prescribing or Dispensing	Any individual who is licensed to prescribe medicine (e.g., physician, physician assistant, nurse practitioner) may prescribe and order administration by qualified staff.	Only licensed physicians who are DEA registered and either work at an OTP or have obtained a waiver to prescribe buprenorphine may do so.	Only licensed physicians who are DEA registered and who work at an OTP can order methadone for dispensing at the OTP.
Abuse and Diversion Potential	No	Yes	Yes
Additional Requirements	None; any pharmacy can fill the prescription.	Physicians must complete limited special training to qualify for the DEA prescribing waiver. Any pharmacy can fill the prescription.	For opioid dependence treatment purposes, methadone can only be purchased by and dispensed at certified OTPs or hospitals.

FDA approved in 2006 for the treatment of alcoholism
FDA approved in 2011 for the treatment of heroin addiction



Hydration



Diffusion



Erosion



As a part of psychosocial support:
Reduces cravings
No potential of abuse (non-addictive, non-euphorigenic)
Decreases impulsivity
Enhances motivation

Improves treatment adherence
Eliminates daily adherence decisions
Single injection is effective for four weeks
Rapid onset of therapeutic effect in the first 2 days

Where We Are


مرکز رشد پرسیس ژن
Persis Gen
پرسیس ژن
مرکز رشد فناوری فرآورده های بیولوژیک
مرکز رشد پرسیس ژن
سایت ۱
سایت ۲
سایت ۳
سایت ۴
سایت ۵
سایت ۶






KATO





Azar Darvazeleri



CRANES
10t


品放置区

About To Be Global





Thank you

For your interest in NANO DARU

No.33, East Baqerkhan St., Chamran Highway, Tehran, Iran

info@nanodaru.com

+98 21 66576271

www.nanodaru.com

Nano Daru